{
    "root": "303be045-4d28-7252-e063-6394a90a3548",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "LISINOPRIL",
    "value": "20250313",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "LISINOPRIL",
            "code": "E7199S1YWR"
        }
    ],
    "indications": "Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3)",
    "contraindications": "Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily (2.1) Pediatric patients with glomerular filtration rate > 30 mL/min/1.73 m 2 : Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily (2.1) Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily (2.2) Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily (2.3) Renal Impairment: For patients with creatinine clearance ≥ 10 mL/min and ≤ 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the recommended initial dose is 2.5 mg (2.4)",
    "warningsAndPrecautions": "5 mg Tablets:yellow, capsule-shaped tablets, imprinted with ‘H 145’ on one side and plain on the other side.\n\n \n                  NDC 43063-074-30 Bottles of 30 tablets \n    NDC 43063-074-90 Bottles of 90 tablets",
    "adverseReactions": "Lisinopril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lisinopril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor\n \n  [see Warnings and Precautions (5.2)].\n\n \n                  Lisinopril is contraindicated in patients with:\n                  \n                     a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor\n                     hereditary or idiopathic angioedema\n                  \n                  Do not co-administer aliskiren with lisinopril in patients with diabetes\n \n  [see Drug Interactions (7.4)]."
}